Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Endocrine Disease Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PRLR drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PRLR ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View PRLR Products |
| Gene Delivery | PRLR Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and signaling validation. |
View PRLR Products |
| Benchmark Ab | Anti-PRLR (Sequence of LTI-291 / clinical candidates) Recombinant positive control for binding and blocking assays. |
View PRLR Products |
| Validator | PRLR siRNA Set For target knockdown verification and pathway specificity controls. |
View PRLR Products |
| Related Target A | JAK2 Downstream tyrosine kinase critical for mediating PRLR-induced JAK-STAT signaling pathways. |
View JAK2 Products |
| Related Target B | HER2 Frequently co-expressed in breast cancers; critical for studying receptor crosstalk and bispecific targeting. |
View HER2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus PRLR ortholog proteins available with >95% purity. |
| Subfamily counter-screening | Homolog panel proteins (Growth Hormone Receptor, GHR) strictly verified by mass spectrometry. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration. |
| False Positives | Validated siRNA included for target-specific knockdown verification. |
Live PRLR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PRLR therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies (mAbs) to Antibody-Drug Conjugates (ADCs) and tissue-targeted blocking agents. As first-generation therapies for hyperprolactinemia and oncology reach advanced clinical phases, the next wave of R&D is targeting non-oncology indications like female pattern baldness (androgenetic alopecia) and endometriosis, where PRLR signaling plays a critical pathogenic role.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugates (ADC) | AbbVie, Regeneron | Breast Cancer, Prostate Cancer | Internalization Assay (Need high-purity, native glycosylated ECD-Fc) |
| Neutralizing mAbs | Bayer, Hope Biosciences | Endometriosis, Alopecia | Ligand-blocking assay (Need high-affinity recombinant Prolactin & PRLR) |
| Bispecific Antibodies | Academic institutions, Biotech startups | Refractory Solid Tumors | Heterodimer validation (Need cross-reactive targets & screening panels) |